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Antisense oligonucleotides (ASOs) are versatile molecules that can be designed to specifically alter splicing
patterns of target pre-mRNAs. Here we exploit this feature to phenocopy a genetic disease. Spinal muscular
atrophy (SMA) is a motor neuron disease caused by loss-of-function mutations in the SMN1 gene. The related
SMN2 gene expresses suboptimal levels of functional SMN protein due to alternative splicing that skips exon 7;
correcting this defect—e.g., with ASOs—is a promising therapeutic approach. We describe the use of ASOs that
exacerbate SMN2 missplicing and phenocopy SMA in a dose-dependent manner when administered to transgenic
Smn–/– mice. Intracerebroventricular ASO injection in neonatal mice recapitulates SMA-like progressive motor
dysfunction, growth impairment, and shortened life span, with a-motor neuron loss and abnormal neuromuscular
junctions. These SMA-like phenotypes are prevented by a therapeutic ASO that restores correct SMN2 splicing.
We uncovered starvation-induced splicing changes, particularly in SMN2, which likely accelerate disease
progression. These results constitute proof of principle that ASOs designed to cause sustained splicing defects can
be used to induce pathogenesis and rapidly and accurately model splicing-associated diseases in animals. This
approach allows the dissection of pathogenesis mechanisms, including spatial and temporal features of disease
onset and progression, as well as testing of candidate therapeutics.
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RNA splicing requires recognition of pre-mRNA cis-
acting elements by spliceosome components and auxil-
iary RNA-binding proteins (Cartegni et al. 2002). Syn-
thetic antisense oligonucleotides (ASOs) can be designed
to base-pair with high specificity to a cis-element on
a given pre-mRNA so as to hinder binding of splicing
activators or repressors, thereby altering splicing pat-
terns. Based on these properties, ASOs are being devel-
oped as RNA-targeted therapeutics to correct disease-
associated splicing defects or—in the case of Duchenne
muscular dystrophy (DMD)—to skip exons and suppress
frame-disrupting mutations (Bennett and Swayze 2010).
Spinal muscular atrophy (SMA) is characterized by
skeletal muscle weakness due to progressive loss of
a-motor neurons. A decrease in SMN protein, one of
whose functions is to promote small nuclear ribonu-
cleoprotein particle (snRNP) assembly, is responsible
for SMA, although how this causes motor neuron
degeneration is not understood (Burghes and Beattie
2009). SMA results from loss of SMN1; humans have
a closely related SMN2 gene that predominantly ex-
presses defective SMN due to alternative splicing of
exon 7. SMN2 is a disease modifier, reducing disease
severity with increased copy number (Burghes and Beattie
2009).
Mice have only one Smn gene, which is essential
(Burghes and Beattie 2009). Introduction of a human SMN2
transgene rescues embryonic lethality, and the resulting
mice (Smn/ SMN2) have SMA-like phenotypes whose
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severity depends on the transgene copy number (Burghes
and Beattie 2009; Park et al. 2010a). Severe ‘‘type I’’ SMA
mice harboring two SMN2 copies, with or without an
additional SMND7 cDNA transgene, die shortly after
birth (<1–2 wk) (Burghes and Beattie 2009; Park et al.
2010a), whereas mild ‘‘type III’’ SMA mice harboring four
SMN2 copies survive normally without paralysis but
develop tail and ear necrosis (Hsieh-Li et al. 2000; Park
et al. 2010a). These strains, while extremely useful, fall
short of providing phenotypically accurate models for
intermediate ‘‘type II’’ SMA that would allow detailed
analyses of phenotype, pathophysiology, and therapeutic
efficacy. Other SMA models with point mutations
(Smn2B/ mice) or exon deletions (SmnF7/D7, NSE-Cre
mice) in murine Smn have intermediate phenotypes, in-
cluding an ;1-mo life span and progressive motor dys-
function with relevant pathological features (Park et al.
2010a); however, these genotypes are not present in SMA
patients and are incompatible with therapeutic strategies
involving splicing correction or up-regulation of the
human SMN2 gene.
We previously showed that a 29-O-(2-methoxyethyl)
(MOE) therapeutic ASO (ASO-10-27) that promotes
exon 7 inclusion rescues tail and ear necrosis in type
III mice; this ASO is metabolically stable in CNS tissues
and corrects SMN2 splicing in the spinal cord for >6 mo
(Hua et al. 2010). Thus, ASOs can persistently control
phenotypes through splicing modulation in the CNS.
This property prompted us to attempt to generate a useful
mouse model of intermediate SMA using ASOs comple-
mentary to a different site on SMN2 pre-mRNA so as to
exacerbate exon 7 missplicing and promote pathogenesis.
Here we demonstrate that intracerebroventricular (ICV)
injection of exon-skipping MOE ASOs in mild type III
neonatal mice accurately phenocopies more severe SMA
symptoms and histopathology as a result of SMN2 mis-
splicing. Treatment with therapeutic ASO-10-27 corrects
the splicing and ameliorates the SMA phenotypes. Fur-
thermore, we report that the SMN2 splicing defect is
exacerbated as a result of starvation, which correlates with
prognosis. We propose that ASOs can serve as useful tools
to develop various animal disease models by persistent
modulation of splicing.
Results
ASO inhibition of SMN2 splicing
Based on our previous screen of ASOs tiled along SMN2
exon 7 (Hua et al. 2007), we designed two new ASOs:
ASO-20-37 and ASO-23-42 (Fig. 1A; Supplemental Table
S1). Their target sites in exon 7 comprise potent enhancer
elements (Lunn and Wang 2008). We used MOE phos-
phorothioate ASOs, which do not trigger RNase H
cleavage or RNAi (Crooke 2007). Their splicing inhibitory
potencies were initially assessed by RT–PCR in type I
SMA patient fibroblasts; both ASOs considerably de-
creased exon 7 inclusion (;10-fold and ;30-fold reduc-
tion by 100 nM ASO-20-37 and ASO-23-42, respectively)
(Fig. 1B).
These ASOs are specific for SMN1/2, so to determine
whether we could phenocopy SMA pathology, we used
them to target an SMN2 transgene in type III SMA mice
(Smn/ SMN2+/+) with normal motor function and life
span (Hsieh-Li et al. 2000). We followed these phenotypes
to determine whether they could be exacerbated by ASO-
mediated splicing modulation. Severe SMA patients
show initial symptoms during the newborn and early-
infant periods (Lunn and Wang 2008). In addition, the
blood–brain barrier (BBB) limits the access of systemically
administered MOE ASO to the CNS (Crooke 2007; Hua
et al. 2008, 2011). Therefore, we used direct administra-
tion into the cerebroventricular space in neonatal mice,
which delivers ASOs via cerebrospinal fluid (CSF) to the
brainstem and spinal cord, the loci of a-motor neurons
Figure 1. ASO-induced inhibition of SMN2 splicing and SMN
expression. (A) SMN2 exon 7 sequence and schematic represen-
tation of ASOs. The core splicing enhancer region is in bold
italic, and bars depict ASOs complementary to the correspond-
ing sequences. (B) RT–PCR shows strong inhibition of SMN2
exon 7 inclusion 48 h after transfection of 100 nM ASO into
SMA patient fibroblasts. (C) Inhibition of exon 7 inclusion in the
P7 mouse spinal cord. (D, left) Western analysis of three rep-
resentative samples shows marked reduction in SMN expres-
sion at both P7 and P30. (Right) For full-length SMN, the top
band in each doublet was quantitated (n = 4). (*) P = 0.0454; (**)
P = 0.0049. (E) Dose response study of ASO-20-37 effects in the
P7 spinal cord. (F) Dose response study of ASO-20-37 effects in
P7 tissues. (FL) Full-length transcripts; (D7) exon 7-skipped
transcripts; (% incl) the percentage of full-length transcripts in
total transcripts. Control (20 mg of control ASO) or, for C and D,
ASO-20-37 or ASO-23-42 (20 mg) was ICV-injected at P1. Error
bars, SD.
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(Hua et al. 2010). We used a single 20-mg (14.2 mg/kg)
injection at postnatal day 1 (P1) and analyzed SMN2
splicing at P7 in the spinal cord. We focused our analysis
on the thoracic cord region but observed similar effects
throughout the spinal cord (Supplemental Fig. S1A). Both
ASO-20-37 and ASO-23-42 potently decreased exon 7
inclusion (approximately fourfold and approximately
threefold reduction, respectively), whereas a mismatch
control ASO had no effect (Fig. 1C; Supplemental Fig.
S1B; Supplemental Table S1). ASO-20-37 was slightly
more effective than ASO-23-42, whereas the opposite
was observed in patient fibroblasts (Fig. 1B), reflecting
size-dependent differences in ASO uptake between cell
transfection and spontaneous in vivo delivery, species-
dependent pharmacokinetics, or different genetic back-
grounds, cell types, and/or developmental stages, each of
which can affect alternative splicing regulation (Cartegni
et al. 2002). Immunoblotting revealed an approximately
fivefold reduction in SMN expression at P7 by ASO-20-37
treatment (Fig. 1D).
Focusing on ASO-20-37, we found that it inhibited
exon 7 inclusion in a dose-dependent manner (Fig. 1E).
Because of CSF clearance, ICV-injected ASO partially
distributes to the peripheral tissues (Hua et al. 2010,
2011); therefore, we analyzed its effects in other tissues.
For muscle, we analyzed proximal quadriceps because
motor tests pointed to a decline in hindlimb strength that
limits essential behaviors (see below). Exon 7 splicing
inhibition was comparable in the brain and spinal cord,
whereas in peripheral tissues, ASO-20-37 had little or no
effect (Fig. 1F).
MOE chemistry minimizes neuroinflammation and is
well tolerated (Crooke 2007; Bennett and Swayze 2010;
Hua et al. 2010), consistent with the very subtle increase
in Aif1 mRNA expression—a macrophage activation
marker—in the P14 spinal cord of mice injected with 20
mg of ASO-20-37 (Supplemental Fig. S2). Aif1 expression
increased at P35 for the test ASO but not a control ASO,
probably reflecting the disease process.
SMN2 splicing deterioration in terminal stage SMA
To determine the duration of the ASO effect, we mea-
sured SMN2 splicing at P30. Compared with the effects at
P7, exon 7 inclusion was further suppressed in the spinal
cord (;15-fold and approximately fivefold reduction by
treatment with 20 mg of ASO-20-37 and ASO-23-42,
respectively) (Fig. 2A,B). Accordingly, there was a further
reduction in SMN protein (;12-fold) (Fig. 1D). In contrast
to P7 mice, we observed increased missplicing in periph-
eral tissues at P30 (Fig. 2C) despite minimal ASO uptake
(Supplemental Fig. S7B). Simultaneous skipping of exons
7 and 5 also increased in 20-mg or 30-mg ASO-20-37-
treated mice (Supplemental Fig. S3A), suggesting indirect
inhibition of SMN2 splicing in response to ASO treat-
ment. Furthermore, extensive exon 7 skipping occurred
systemically at P35 (Fig. 2D), the terminal stage for mice
injected with 20 mg of ASO (see below). The finding that
the level of SMN2 splicing at P14 (Fig. 2E) was similar to
that at P7 (‘‘20 mg’’ lanes in Fig. 1E,F) suggests that SMN2
splicing is subsequently suppressed at P30–P35 because
of the end-stage disease state, rather than by a persistent
ASO effect. Consistent with this interpretation, neonatal
ICV injection of therapeutic ASO-10-27 with the same
chemical modifications had reduced or no effect in the
P30 spinal cord, liver, or heart compared with that at P7
(Supplemental Fig. S3B; Hua et al. 2010).
As a further test, we compared SMN2 splicing in
untreated P1 or P7–P8 type I SMA mice (Smn/
SMN2+/0) with that in type III mice (Smn/ SMN2+/+)
or healthy mice (Smn+/+ SMN2+/0 and Smn+/ SMN2+/0).
At P7–P8, type I mice typically looked severely malnour-
ished and moribund, and exon 7 inclusion in their spinal
cord decreased at this time, whereas it increased in type
III or healthy mice (Fig. 3A; Supplemental Fig. S4A). A
similar trend was observed in the heart between type I
and III mice (Fig. 3A).
These results suggest that SMN2 splicing is suppressed
as a result of nutritional deficiency, considering that
dying SMA mice have poor food intake and extensive
weight loss. To directly test this hypothesis, we subjected
untreated type III mouse pups or adults to food depriva-
tion; after 48 h, SMN2 splicing was markedly inhibited in
both the CNS and peripheral tissues (Fig. 3B), especially
in pups. Remarkably, when these pups were fed again,
SMN2 splicing was restored, demonstrating a nutritional
Figure 2. Time-course RT–PCR analysis of SMN2 splicing
inhibition. (A) Further inhibition of exon 7 inclusion in the
P30 spinal cord. (B) Dose response study of ASO-20-37 effects at
P30. For A and B, bar graphs also display P7 data from Figure 1,
C and E, respectively. (C) Increased difference in SMN2 splicing
level at P30 between control and ASO-20-37-treated mice.
(D) Systemic exon 7 skipping in ASO-20-37-treated mice at
P35. (E) SMN2 splicing level at P14 was similar to that at P7.
Control (20 mg of control ASO) or, for A and C–E, ASO-20-37 or
ASO-23-42 (20 mg) was ICV-injected at P1. Error bars, SD.
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effect on splicing (Fig. 3C). Importantly, this inhibition of
SMN2 splicing was also observed in the spinal cord of
food-deprived wild-type transgenic mice (Smn+/+ SMN2+/+)
(Supplemental Fig. S4B).
Widespread splicing abnormalities were reported in
late stage type I mice, although whether these are the
cause or consequence of SMA progression is controversial
(Zhang et al. 2008; Baumer et al. 2009). We analyzed
previously reported splicing alterations of Uspl1 and
Chodl (Zhang et al. 2008; Baumer et al. 2009) in the spinal
cord of P7 or P30 ASO-20-37-treated mice. RT–PCR
demonstrated abnormal splicing of both pre-mRNAs,
especially at P30 (Supplemental Fig. S5A). In contrast,
splicing of these genes was not altered at P7 in normal
mice (Smn+/+) treated with ASO-20-37 (Supplemental Fig.
S5B). Splicing was also altered in food-deprived but other-
wise untreated type III mice (Supplemental Fig. S5C),
indicating that these splicing abnormalities are not a direct
consequence of ASO-20-37 treatment.
ASO induction of SMA-like phenotypes
Both ASOs elicited ‘‘SMA-like’’ phenotypes. ICV injection
of 20 mg of ASO at P1 strikingly shortened the life span
of type III SMA mice, and ASO-20-37 was more potent
than ASO-23-42 (median survival 33 vs. 41 d; P < 0.0001)
(Fig. 4A). Focusing on ASO-20-37, we observed a dose-
dependent reduction in survival and weight gain (Fig.
4A–C). There was no change in the onset or progression
of tail necrosis (Fig. 6C, below). With respect to motor
dysfunction—a cardinal SMA symptom—the mice ex-
hibited a staggering gait with short strides (Supplemental
Fig. S6A; Supplemental Movies) that became apparent
around weaning. Dose-dependent motor impairment was
evident in rotarod and grip strength tests (Fig. 4D; Supple-
mental Fig. S6B).Moreover, a video-based analysis of home
cage behaviors showed declined locomotor activity, in-
cluding decreases in standing, eating, and hanging (Fig. 4E).
These physiological tests were mainly performed at P25–
P26, when mice injected with 20 mg of ASO-20-37 grew
large enough to perform the rotarod task. Although ASO-
20-37-treated mice had a normal righting reflex until P12
(Supplemental Fig. S6C) and maintained grip strength at
P15 and P22 (Supplemental Fig. S6D), once the abnormal
gait occurred, their locomotor activity declined progres-
sively, culminating in death. Both ASO-20-37- and ASO-
23-42-treated mice also displayed systemic tremor (Sup-
plemental Movies).
Supportive SMA histological features
a-Motor neuron degeneration is the pathological hallmark
of SMA (Lunn and Wang 2008). In ASO-20-37-treated mice,Figure 3. SMN2 splicing inhibition in end-stage SMA and as
a result of starvation. (A) Changes in SMN2 splicing in the type I
or type III SMA mouse spinal cord and heart between P1 and P7.
(B) Forty-eight hours of fasting caused exon 7 skipping in both
CNS and non-CNS tissues of type III SMAmouse pups or adults.
(C) SMN2 splicing was restored at P28 once fasted pups were fed
after food deprivation at P7–P9. Error bars, SD.
Figure 4. ASO induction of SMA-like symptoms. (A) Shortened
life span. The number of mice and median survival in days are
given in parentheses for each group. (B) Decreased body weight
gain. (C) Smaller ASO-20-37-treated mice. (D) Motor dysfunc-
tion. Rotarod task performance (n = 6; [*] P = 0.0002; [**] P <
0.0001) and grip strength (n = 10; [*] P = 0.0180; [**] P < 0.0001).
P22 control mice of the same size as P26 ASO-20-37-treated
mice were included. (E) Video-based analysis of home cage
behaviors at P26 (n = 8). (*) P = 0.0143. (Normal) Normal mice.
Control (20 mg of control ASO) or, for C–E, ASO-20-37 (20 mg)
was ICV-injected at P1. Error bars, SD.
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immunohistochemistry (IHC) of the lumbar spinal cord
showed significant loss of choline acetyltransferase
(ChAT)-positive a-motor neurons at P30 but not at P16
(Fig. 5A; Supplemental Fig. S7A). In contrast, there was
a small but not significant loss in the cervical spinal cord
at P30 (Supplemental Fig. S7A). IHC with antibody
against the phosphorothioate backbone showed that
motor neurons in the lumbar spinal cord still have in-
ternalized ASO at P30 (Fig. 5B). SMN-positive nuclear
gem counts, which correlate directly with functional SMN
protein level and inversely with SMA severity (Lunn and
Wang 2008), decreased markedly (Fig. 5C). This SMN
decrease probably triggers neuronal dysfunction and sub-
sequent degeneration.
Groups of atrophic fibers are seen in quadriceps of type I
mice (Hsieh-Li et al. 2000). However, we did not observe
this feature (Supplemental Fig. S7D), which would have
been indicative of a prepathological stage preceding rapid
disease progression (Dubowitz and Sewry 2007). Recent
reports described structural and electrophysiological de-
fects in the neuromuscular junction (NMJ) in severe SMA
(Burghes and Beattie 2009). We analyzedNMJ pathology in
several vulnerable muscles that are affected in SMA D7
mice (Ling et al. 2012). Acetylcholine receptor (AChR)
clusters at the NMJ are initially plaque-shaped; later,
perforated plaque, fold/C-shaped, branched, and pretzel-
shaped structures become successively more prevalent as
development proceeds (Kummer et al. 2004). In ASO-20-
37-treated mice at P30, immunofluorescence staining for
NMJs in the longissimus capitus (LC) and serratus poste-
rior inferior (SPI) showed smaller AChR clusters with
reduced topological complexity; there were fewer mature
pretzel and branched forms and more of the less mature
forms (Fig. 5D; Supplemental Fig. S7C). Moreover, fully
innervated NMJs (see the Materials and Methods) were
markedly reduced in the LC (Fig. 5D). There was a small
reduction in the extent of innervation in the splenius
capitus, but little or no reduction in the SPI and extensor
Figure 5. ASO effects on mouse histopathology. (A) a-Motor neuron loss. (Left) DAB staining with or without ChAT antibody of
a-motor neurons in P30 lumbar spinal cord. Bar, 500 mm. (Right) a-Motor neuron counts (n = 3). (*) P = 0.0171. (B) Detection of ASO
uptake in P30 spinal cord cells, including a-motor neurons, by IHC. For A and B, a-motor neurons are displayed at higher magnification
in the insets. (C) Decreased nuclear gems. (Left) Dual ChAT and SMN staining of a-motor neurons in the P30 lumbar spinal cord. Bar,
50 mm. (Right) Nuclear gem counts in a-motor neurons (n = 4). (*) P = 0.0001. (D) NMJ defects in the P30 LC. (Top) NMJs were labeled
with anti-neurofilament (NF; blue) for nerves, anti-synaptophysin (Syn; green) for nerve terminals, and a-bungarotoxin (a-BTX; red) for
AChRs on the postsynaptic muscle. Bar, 40 mm. (Bottom left) Reduced topological complexity of AChR clusters (elaborate pretzels; n =
3). (*) P = 0.0300. (Bottom right) Denervated NMJs at P30 but not at P16 (n = 3). (*) P = 0.0335. Control (20 mg of control ASO), saline (2
mL of saline), or ASO-20-37 (20 mg of ASO-20-37) was ICV-injected at P1. Error bars, SD.
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digitorum longus (Supplemental Fig. S7C). The preser-
vation of a-motor neuron counts, AChR topology, and
NMJ innervation in the LC at P16 (Fig. 5D; Supplemen-
tal Fig. S7A) is consistent with the progressive nature of
the disease. Taken together, these results show that
ASO-20-37-treated mice recapitulated the characteristic
severe SMA pathology.
Finally, there is cardiac involvement in severe SMA
(Rudnik-Schoneborn et al. 2008; Bevan et al. 2010), but we
detected no evidence of inflammation in heart sections
at P30, such as cell infiltration and increased interstitial
fibrosis (Supplemental Fig. S7E). At the terminal stage,
however, some ASO-20-37-treated mice manifested paw
and face edema and tachypnea, indicative of cardiac and/
or respiratory failure, despite only faint ASO uptake in
the heart, lung, and diaphragm at P30 (Supplemental Fig.
S7B). To characterize the cardiac phenotype, hearts were
harvested and weighed at P30. Consistent with a study
of type I mice (Bevan et al. 2010), the heart mass was
reduced, even when normalized to femoral length (Sup-
plemental Fig. S7E). In addition, there was an increase
in interventricular septal thickness, normalized to the
heart mass (Supplemental Fig. S7E), suggesting cardiac
involvement.
Amelioration of SMA-like symptoms
by a therapeutic ASO
We previously reported an ASO complementary to posi-
tions +10 to +27 in SMN2 intron 7 (ASO-10-27) (Supple-
mental Table S1) that blocks a splicing silencer element,
strongly increasing exon 7 inclusion (Hua et al. 2008).
This therapeutic ASO-10-27, when administered by neo-
natal ICV and/or systemic subcutaneous (SC) injection,
effectively rescues both type I and type III mouse pheno-
types (Hua et al. 2010, 2011; Passini et al. 2011). Here we
tested whether it could also rescue SMN2 splicing in
ASO-20-37-treated mice and thus influence the pheno-
type. The binding site of therapeutic ASO-10-27 in intron
7 does not overlap with that of ASO-20-37 in exon 7, and
thus these ASOs do not directly affect each other’s
binding to SMN2 pre-mRNA. After ICV injection of 20
mg of ASO-20-37 at P1, we administered ASO-10-27 by
ICV or systemic SC injection. ICV injection of 20 mg of
ASO-10-27 at P2markedly extended the life span (median
survival >100 d, P < 0.0001) (Fig. 6A) with improved
weight gain (Fig. 6B) and slightly delayed onset of tail
necrosis (Fig. 6C). The treatment also improved motor
function (Fig. 6D) and correspondingly prevented a-motor
neuron loss (Fig. 6E) and preserved normal AChR topol-
ogy and NMJ innervation (Fig. 6F). In contrast, SC in-
jection of ASO-10-27 (50 or 200 mg/g per day at both P2
and P3) only had a slight effect on survival (median
survival, 50 mg/g/ per day: 40 d, P < 0.0001; 200 mg/g per
day: 41 d, P < 0.0001) (Fig. 6A). However, it moderately
improved weight gain and motor function (Fig. 6B,D) and
markedly rescued tail necrosis (Fig. 6C). RT–PCR showed
that ICV-injected ASO-10-27 restored SMN2 splicing in
the spinal cord to the control level but had little or no
effect in the liver, heart, and muscle, whereas SC in-
jection only had a small effect in the spinal cord but
significant effects in peripheral tissues, especially in the
liver, as we previously reported (Fig. 6G; Hua et al. 2008,
2010, 2011). These results indicate that the extent of
exon 7 skipping in the spinal cord is the main determi-
nant of the SMA-like symptoms induced by ICV admin-
istration of ASO-20-37 and also support ASO-10-27 as
a drug candidate.
Discussion
We applied exon-skipping ASO technology to phenocopy
a motor neuron disease by postnatally inhibiting SMN2
splicing in transgenic mice. We successfully elicited
phenotypes resembling core SMA symptoms, thus exac-
erbating the phenotype of a mild SMA mouse model. To
promote exon skipping, we selected ASOs targeting splic-
ing enhancer sequences within exon 7 of SMN2, in part to
avoid interference with the target site of ASO-10-27 in
intron 7. This made it possible to perform splicing rescue
experiments using ASO-10-27.
Because SMA primarily affects a-motor neurons, we
assumed that SMN2 splicing in the brainstem and spinal
cord would be critical. We used ICV administration for
direct ASO delivery to the CNS, and a single injection had
significant, dose-dependent effects on both SMN2 splic-
ing and the phenotypes (Figs. 1, 4). As with type I mice
(Park et al. 2010a) or severe SMA patients (Lunn and
Wang 2008; Rudnik-Schoneborn et al. 2008), growth
impairment and cardiac involvement likely influenced
the prognosis of ASO-20-37-treated mice (Supplemental
Fig. S7). With an ;1-mo life span and overt SMA-like
phenotypes that are partly shared by Smn2B/ or SmnF7/D7,
NSE-Cre mice (Park et al. 2010a), thesemice are especially
useful for analyses of disease progression, physiological
tests, and therapeutic efficacy.
Although ICV-administered MOE ASOs distribute
throughout the CNS, they are partly cleared out of the
CNS and accumulate in peripheral tissues (Supplemental
Fig. S7). However, because of a combination of low dose,
ASO dilution in plasma and tissues, much shorter half-
life in peripheral tissues, and renal excretion (Crooke
2007), any pharmacological effects outside the CNS are
likely minimal. Indeed, ASO-20-37 predominantly inhibited
SMN2 splicing in the CNS and resulted in a-motor neuron
loss (Fig. 5). The nuclear gem number, an indicator of
SMN abundance (Lunn and Wang 2008), decreased mark-
edly in a-motor neurons (Fig. 5), which could cause
neuronal dysfunction. On the other hand, similarly to
SMA D7 mice (Ling et al. 2012), ASO-20-37-treated mice
exhibited NMJ defects (Fig. 5). Until P16, the LC NMJs
attained full innervation, and the AChR clusters contin-
ued to mature normally. The reduced complexity of
AChR topology at P30 might be attributed to rapid AChR
turnover and/or impairment of further maturation due to
NMJ denervation (Fambrough 1979) under conditions of
a-motor neuron dysfunction after P16. Alternatively or
additionally, ASO-20-37 might have a direct effect in
muscle that alters endplate maturity. The ASO-mediated
postnatal induction of SMA pathology reveals that SMN
Antisense modeling of disease
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is required for a-motor neurons after completion of their
genesis around embryonic day 11 (Nornes and Carry
1978). Conversely, restoring SMN levels shortly after
birth is therapeutically effective for severe SMA mice
(Hua et al. 2011; Le et al. 2011; Lutz et al. 2011),
consistent with a role of SMN in the postnatal develop-
ment of motor neurons.
Compared with SC administration of therapeutic ASO-
10-27, ICV administration considerably extended the life
span and alleviated motor dysfunction of ASO-20-37-
treated mice, implying that SMN2 splicing correction in
the CNS is necessary and sufficient for phenotypic and
histological amelioration (Fig. 6). In contrast, we pre-
viously found that neonatal SC administration of ASO-
10-27 markedly extends the life span of type I mice (Hua
et al. 2011). In that case, SMN restoration in peripheral
tissues was necessary for efficient rescue, although an
additional direct effect in the CNS was not excluded.
The apparent inconsistency between the two studies
may reflect the fact that here SMN2 splicing was pre-
dominantly inhibited in the CNS, in contrast to the
ubiquitous SMN2 splicing defect in type I mice (or human
SMA). Another important difference is that here SMN
depletion was induced postnatally, whereas it occurs
embryonically in type I mice. The BBB in our mice might
be more intact compared with that in type I mice, which
in the present study might reduce the CNS effects of
systemically administered ASO-10-27. However, the
present results suggest that the SMN level in the CNS
is critical for the SMA phenotype as well as its severity.
On the other hand, SC administration of ASO-10-27
markedly rescued tail necrosis, whereas ICV administra-
tion only had a subtle effect, implying that peripheral
SMN levels are more relevant for distal necrosis. In-
complete closure of the BBB in neonates (Stewart and
Hayakawa 1987) and/or retrograde axonal transport of
ASO (Crooke 2007) to spinal cord neurons might also
contribute to the rescue of tail necrosis by peripheral ASO
administration, which would be consistent with our
previous finding that ICV administration of therapeutic
ASO-10-27 rescues tail necrosis in type III SMA mice
(Hua et al. 2010).
SMN depletion in motor neuron progenitors results
in relatively mild SMA-like phenotypes, suggesting that
Figure 6. Amelioration of ASO-20-37-treated mouse phenotype by therapeutic ASO-10-27. (A) Extended survival. The number of mice
and median survival in days are given in parentheses for each group. (B) Increased body weight. (C) Delayed onset of tail necrosis. (D)
Improved motor function. Rotarod task performance at P26 ([*] P = 0.0014; [**] P < 0.0001) and grip strength ([*] P = 0.0035; [**] P <
0.0001). (E) Retained a-motor neurons in the P30 lumbar spinal cord by ICV injection of ASO-10-27. (n.s.) P = 0.1252; (*) P = 0.0054. (F)
Retained NMJs in the P30 LC. (Left) NMJs were labeled as in Figure 5D. Bar, 40 mm. (Middle) Recovered topological complexity of
AChR clusters (elaborate pretzels; n = 3). (*) P = 0.0335. (Right) Intact NMJ innervation (n = 3). (*) P = 0.0003. (G) Restoration of SMN2
exon 7 splicing in P8 tissues. (+ASO-10-27 ICV) ICV injection of 20 mg of ASO-10-27 at P2; (+ASO-10-27 SC50 or SC200) SC injection of
50 or 200 mg/g per day ASO-10-27 at P2 and P3, respectively. Error bars, SD.
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other cells also contribute to SMA pathogenesis (Park
et al. 2010b). As our ASOs do not exclusively target
a-motor neurons (Fig. 5; Supplemental Fig. S7; Hua et al.
2010; Passini et al. 2011), their effects in other cells
could also have contributing roles in this SMA model.
Considering the potential developmental component of
SMA, the ASO effects at different developmental stages
also need to be addressed. Further analysis of the re-
lationship between the spatial and/or temporal distribu-
tion of ASOs that promote correct or incorrect SMN2
splicing, and their pharmacological effects, should yield
new insights into the roles of SMN in SMA pathogenesis
as well as its normal physiological functions.
SMN2 splicing deteriorated further in dying SMA mice
(Figs. 2, 3), and we demonstrated that nutritional status
affected splicing even in mild type III or wild-type trans-
genic mice in the absence of any ASO (Fig. 3; Supplemen-
tal Fig. S4). Widespread splicing changes were reported in
late stage type I mice (Zhang et al. 2008; Baumer et al.
2009), and indeed we confirmed altered splicing of two
representative genes,Uspl1 and Chodl, both in our ASO-
induced SMA mice—especially at the terminal stage—
and in food-deprived but untreated type III mice (Supple-
mental Fig. S5). The splicing changes that we uncovered
in SMN2 transgene transcripts during late stage SMA
were not described in these studies, although in other
studies, SMN2 splicing was shown to decrease in type I
mice at P1 (Jodelka et al. 2010; Ruggiu et al. 2012). Dying
mice likely suffer from hypoxia; hypoxic stress induces
reactive oxygen species generation, which inactivates
the SMN complex (Wan et al. 2008). This complex plays
fundamental roles in assembling snRNPs, which are
required for splicing (Burghes and Beattie 2009), and low
SMN levels result in decreased SMN2 exon 7 splicing
through a feedback loop (Jodelka et al. 2010; Ruggiu et al.
2012). Thus, under critical dying conditions, including
malnutrition and hypoxia, SMA may progress with grad-
ual, widespread splicing alterations in which the result-
ing SMN dysfunction and deficiency could be partly
involved.
RNA-targeted methods for generating animal disease
models have largely focused on RNAi-based or antisense
knockdown approaches (Sandy et al. 2005; Crooke 2007).
Compared with these approaches, our method, which we
dubbed TSUNAMI (for targeting splicing using negative
ASOs to model illness) retains the primary transcript,
allowing the testing of therapeutics that correct missplic-
ing. Splicing-modulating ASOs do not cause RNA cleav-
age and thus have fewer potential off-target hybridization
effects than knockdown ASOs or RNAi. Furthermore,
ICV-injected MOE ASO at the effective doses induces
minimal or no chemistry-related neuroinflammation, as
demonstrated by the limited extent of Aif1 mRNA
expression (Supplemental Fig. S2). Indeed, our ASOs did
not affect normal or heterozygote Smn+/ SMN2+/+ mice,
reflecting their species-specific effects on splicing and
ruling out off-target effects (Supplemental Movies). In
addition, two different ASOs targeting SMN2 exon 7
elicited the same SMA-like phenotype, again ruling out
off-target effects. Moreover, the phenotypic amelioration
of ASO-20-37-treated mice with therapeutic ASO-10-27
definitively proved that the SMA-like phenotypes were
induced through SMN2 splicing inhibition.
Although genetic strategies are also very useful for
temporal and spatial regulation of SMN expression in
mice (Park et al. 2010b; Le et al. 2011; Lutz et al. 2011),
TSUNAMI has several advantages: (1) It circumvents the
need to engineer mouse strains, which requires expertise
and time-consuming genetic crosses and characterization
of individual lines. (2) It provides great flexibility in fine-
tuning disease severity simply by changing the ASO dose
or choosing ASOs with different potencies. (3) It can help
to define the relevant tissues and cell types in a given
disease by taking advantage of ASO pharmacokinetic
properties, which depend on the administration route,
chemical modifications, and formulation. (4) It facilitates
the temporal regulation of target gene expression simply
by delivering the ASO at various prenatal or postnatal
stages, varying the dosing frequency, or using different
chemical modifications to adjust the ASO half-life. (5) It
enables the testing of splicing-correcting therapeutics to
prevent, delay, or rescue the disease phenotype.
Exon-skipping ASOs are being used therapeutically,
notably to restore the translational reading frame in
DMD (Aartsma-Rus 2010). In contrast, we demonstrate
here how to use them to generate a disease model.
Previously, systemically administered exon-skipping
ASOs that alter Dmd splicing were shown to decrease
dystrophin expression in the mouse diaphragm and were
used to map functional protein domains of dystrophin
(Fletcher et al. 2010). An important distinction with the
present study is that DMD is mostly caused by intragenic
deletions (Muntoni and Wood 2011) and not typically by
missplicing. Thus, although ASO-induced missplicing
might to some extent phenocopy DMD because of the
reduction in full-length protein, it does not model the
typical genetic defect and is therefore not suitable for
testing some of the current candidate therapeutics for
DMD; namely, exon-skipping ASOs and translational
readthrough compounds (Muntoni and Wood 2011).
In short, we show here that a single ICV injection of
ASO in neonatal mice can phenocopy a neurodegenera-
tive disease, and disease severity can be fine-tuned
through dose-dependent effects on splicing. MOE ASOs
induced SMA-like symptoms and histopathology that pro-
gressed irreversibly in the absence of therapy. TSUNAMI
represents a useful alternative to genetic models based on
stable or conditional knockout/rescue of disease-associ-
ated genes. When transgenic animal models are available,
targeting the human transgene—as we did here—offers
the advantage that TSUNAMI can be used to test the
same candidate therapeutics that would be used in the
clinic. On the other hand, TSUNAMI should be applica-
ble in principle to anymouse strain or any animal species,
although this requires the careful development of species-
specific ASOs that appropriately modulate splicing of the
target gene. Although here we used exon-skipping ASOs
to elicit a splicing defect, and an exon-including ASO to
correct it, our method can be readily adapted to promote
other types of changes in splicing, as appropriate for each
Antisense modeling of disease
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disease and target gene (Kole et al. 2012). Our method
should be compatible with other oligonucleotide chem-
istries as long as the ASOs are internalized by the
appropriate cell types, are able to reach the cell nucleus,
have favorable hybridization properties, do not promote
RNase H cleavage or RNAi, and do not elicit substantial
immune or inflammatory responses or other adverse
effects. Last but not least, TSUNAMI is not at all limited
to modeling CNS diseases: It should also be possible to
use it to alter splicing of target genes expressed in various
tissues using the appropriate administration route and, if
necessary, multiple dosing.
Materials and methods
Oligonucleotide synthesis
29-MOE oligonucleotides with phosphorothioate backbone and
all 5-methylcytosines were synthesized and purified as described
(Hua et al. 2010). ASOs were dissolved in saline and adjusted to
the desired concentration. The ASO sequences are listed in
Supplemental Table S1.
Animals
Mouse protocols were approved by Cold Spring Harbor Labora-
tory’s Institutional Animal Care and Use Committee. Type III
SMA mice (Smn/ SMN2+/+) with four SMN2 copies were
purchased from The Jackson Laboratory [strain FVB.Cg-
Tg(SMN2)2Hung Smn1tm1Hung/J]. Type I SMA mice (Smn/
SMN2+/0) harboring two SMN2 copies were generated as de-
scribed (Gogliotti et al. 2010; Riessland et al. 2010). After
weaning, mice were fed a normal chow diet (PicoLab Rodent
Diet 20, LabDiet) and a nutrient-fortified water gel diet (DietGel
Recovery, ClearH2O).
Neonatal injection
For ICV injection, P1 or P2 neonatal mice were cryo-anesthetized
on ice, and 2 mL of ASO in saline was injected into the right
lateral ventricle using a 5-mL microsyringe (Hamilton) and a 33-
gauge needle. The coordinates for injection were 1 mm lateral
from the sagittal suture, 2 mm anterior from the lambdoid
suture, and 2 mm deep. ICV injections were well tolerated. Fast
Green FCF (0.01% [w/v]; Sigma-Aldrich) was included in the
ASO solution so that the shape of both the lateral and fourth
ventricles could be visualized when the ICV injection was
successful. No leakage was observed around the skull surface.
For SC injection, 1.5–8.0 mL of 50 mg/g ASO in saline—with the
volume adjusted according to the body weight—was injected
into the dorsal skin using a 10-mL microsyringe (Hamilton) and
a 33-gauge needle.
Radioactive RT–PCR and Western blotting
For each group, RT–PCR with 32P-dCTP was performed with
tissues from three mice. Total RNA extraction and RT–PCR
were performed to analyze SMN2 transcripts as described (Hua
et al. 2007, 2008). We previously used both radioactive RT–
PCR and real-time PCR to quantitate SMN2 exon 7-included
and -skipped isoforms with entirely consistent results (Hua
et al. 2010). To analyze Uspl1 or Chodl splicing patterns or
Aif1 expression level, the following PCR primers were used:
Uspl1, forward (59-AGTTCGGGTCCACTGTATGC-39) and re-
verse (59-GGCTTACTTGGAGTGGGACA-39), Chodl, forward
(59-AAGCCGTATCTTACAAACCAACCT-39) and reverse (59-CC
ACTTTCCTTCCTCGTGCT-39), and Aif1, forward (59-CAG
CAATGATGAGGATCTGC-39) and reverse (59-GTTTCTCCAG
CATTCGCTTC-39). Gapdh mRNA levels were analyzed using
the following primers: forward (59-CGTCCCGTAGACAAAAT
GGT-39) and reverse (59-GAATTTGCCGTGAGTGGAGT-39).
PCR products were analyzed by native PAGE and Phosphor-
Image detection (FLA-5100, Fujifilm). Band intensities were
quantitated with Multi Gauge software (Fujifilm). The signal
intensity of each band was normalized according to its GC
content.
Total protein was extracted from the thoracic spinal cord and
analyzed by Western blotting. The blots were probed with
a monoclonal antibody (mAb) specific for human SMN (SMN-
KH) (Hua et al. 2010) or anti-a-tubulin mAb (Sigma-Aldrich),
followed by IRDye-conjugated secondary antibody (LI-COR Bio-
sciences). Protein bands were detected and quantitated with an
Odyssey infrared imaging system (LI-COR Biosciences) as de-
scribed (Hua et al. 2010, 2011).
Cell culture and transfection
Type I SMA patient fibroblasts (GM03813, Coriell Institute) were
cultured as described (Hua et al. 2008). ASOs were transfected
using Lipofectamine 2000 (Invitrogen).
Neurological and behavioral tests
The righting reflex was assessed at P8, P10, and P12. Pups were
placed on their side, and the time elapsed until they placed all
four paws stably on the ground was recorded.
A rotarod task was carried out using a RotaRodIV instrument
(AccuScan). The time to fall from a 7-rpm rotating rod was
measured until an arbitrary limit of 180 sec. Ten sequential trials
were performed, and the longest time was recorded.
Grip strength was measured using a Grip Strength Meter
(Columbus Instruments). Mouse palms were placed on a triangle
bar, and once they grasped it, the mice were pulled back
horizontally until they released it. Six sequential trials were
performed, and the highest value was recorded.
Phenotypic characterization of mouse behavior was per-
formed using a video-based behavior recognition platform (Steele
et al. 2007). Mice were recorded throughout a 12-h dark phase,
and the data were analyzed using HomeCageScan software
(Clever Sys.).
Histology
The formalin-fixed, paraffin-embedded spinal cord was cut into
6-mm sections. After antigen retrieval with citrate buffer (pH
6.0), each section was incubated with goat anti-ChAT antibody
(1:500; Millipore). Immunoreactivity was detected by ImmPress
anti-goat IgG antibody (Vector Laboratories) and DAB substrate
chromogen (Dako), followed by hematoxylin counterstaining.
ChAT-positive a-motor neurons in the anterior horn with
a single nucleolus within the nucleus (>350 mm2) (Friese et al.
2009) were counted in 6-mm, 24 serial sections of L1–L2 spinal
cord. To ensure consistent and nonredundant counting, the total
neuron counts were determined in every eighth section for three
sections, and the counts of the eight groups were averaged. All of
the steps from harvesting through staining of spinal cords were
processed in parallel so as to reduce artifactual variation between
experimental samples. ASO cellular uptake was assessed with
antibody against the phosphorothioate backbone. For dual stain-
ing for SMN and ChAT, the section was incubated with anti-
ChAT antibody (1:500), followed by Alexa Fluor 594 IgG anti-
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body (Invitrogen) and anti-SMN antibody (1:500; BD Biosci-
ences), followed by Alexa Fluor 488 IgG antibody (Invitrogen).
Nuclear gems located within 100 a-motor neurons were counted
in the L1–L2 spinal cord.
For NMJ staining, after perfusing and post-fixing with 4%
paraformaldehyde, wholemuscles were dissected and teased into
layers five to 10 fibers thick. NMJs were immunolabeled with
anti-neurofilament (1:2000; Chemicon) for nerves, anti-synapto-
physin (1:200; Invitrogen) for presynaptic terminals, and Alexa
Fluor 594-conjugated a-bungarotoxin (Invitrogen) for AChRs.
The proportion of fully innervated NMJs was quantified. Fully
innervated NMJs were defined by the complete overlap of pre-
synaptic (i.e., synaptophysin) and post-synaptic (a-bungarotoxin)
labeling. Endplate maturity was assessed by AChR topology, as
described (Kummer et al. 2004), and the percentage of endplates
with mature AChR topology was quantified. For each sample, at
least 100 NMJs were evaluated from random visual fields of the
whole mount. Flash-frozen quadriceps muscle and formalin-
fixed heart were cut into 14- and 7-mm sections, respectively,
at the level of each maximum transection for H&E staining.
Maximum heart interventricular septal thickness was mea-
sured in these sections. Images were acquired with an Axio
Observer.Z1 microscope and an LSM 710 confocal microscope
(Carl Zeiss) for bright-field and immunofluorescence imaging,
respectively.
Statistical analysis
We analyzed data using two-tailed t-tests and considered
P-values #0.05 to be statistically significant. For analysis of
home cage behaviors, we used the Friedman test, a nonparamet-
ric version of ANOVA implemented in Matlab. Kaplan-Meier
survival curves were prepared with Prism 5 (GraphPad), and
statistical significance was calculated with the log-rank (Mantel-
Cox) test. The various histograms and plots showmean values6
standard deviation (SD).
Acknowledgments
We thank Jie Bu and Marco Passini for advice on NMJ staining,
Lisa Bianco for assistance with mouse studies, Raisa Puzis and
Aigoul Nourjanova for help with histological analysis, and
Stephen Hearn for assistance with microscope imaging. We
acknowledge support from the National Institutes of Health, the
Muscular Dystrophy Association, the SMA Foundation, and the
St. Giles Foundation.
References
Aartsma-Rus A. 2010. Antisense-mediated modulation of splic-
ing: Therapeutic implications for Duchenne muscular dys-
trophy. RNA Biol 7: 453–461.
Baumer D, Lee S, Nicholson G, Davies JL, Parkinson NJ, Murray
LM, Gillingwater TH, Ansorge O, Davies KE, Talbot K. 2009.
Alternative splicing events are a late feature of pathology in
a mouse model of spinal muscular atrophy. PLoS Genet 5:
e1000773. doi: 10.1371/journal.pgen.1000773.
Bennett CF, Swayze EE. 2010. RNA targeting therapeutics:
Molecular mechanisms of antisense oligonucleotides as
a therapeutic platform. Annu Rev Pharmacol Toxicol 50:
259–293.
Bevan AK, Hutchinson KR, Foust KD, Braun L, McGovern VL,
Schmelzer L, Ward JG, Petruska JC, Lucchesi PA, Burghes
AH, et al. 2010. Early heart failure in the SMND7 model of
spinal muscular atrophy and correction by postnatal
scAAV9-SMN delivery. Hum Mol Genet 19: 3895–3905.
Burghes AH, Beattie CE. 2009. Spinal muscular atrophy: Why do
low levels of survival motor neuron protein make motor
neurons sick? Nat Rev Neurosci 10: 597–609.
Cartegni L, Chew SL, Krainer AR. 2002. Listening to silence and
understanding nonsense: Exonic mutations that affect splic-
ing. Nat Rev Genet 3: 285–298.
Crooke ST. 2007. Antisense drug technology: Principles, strat-
egies, and applications. CRC Press, Boca Raton, FL.
Dubowitz V, Sewry CA. 2007. Muscle biopsy: A practical
approach. Elsevier, Amsterdam, Netherlands.
Fambrough DM. 1979. Control of acetylcholine receptors in
skeletal muscle. Physiol Rev 59: 165–227.
Fletcher S, Adams AM, Johnsen RD, Greer K, Moulton HM,
Wilton SD. 2010. Dystrophin isoform induction in vivo by
antisense-mediated alternative splicing. Mol Ther 18: 1218–
1223.
Friese A, Kaltschmidt JA, Ladle DR, Sigrist M, Jessell TM, Arber
S. 2009. g and a motor neurons distinguished by expression
of transcription factor Err3. Proc Natl Acad Sci 106: 13588–
13593.
Gogliotti RG, Hammond SM, Lutz C, Didonato CJ. 2010.
Molecular and phenotypic reassessment of an infrequently
used mouse model for spinal muscular atrophy. Biochem
Biophys Res Commun 391: 517–522.
Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH,
Li H. 2000. A mouse model for spinal muscular atrophy. Nat
Genet 24: 66–70.
Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR. 2007.
Enhancement of SMN2 exon 7 inclusion by antisense
oligonucleotides targeting the exon. PLoS Biol 5: e73. doi:
10.1371/journal.pbio.0050073.
Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR. 2008.
Antisense masking of an hnRNP A1/A2 intronic splicing
silencer corrects SMN2 splicing in transgenic mice. Am J
Hum Genet 82: 834–848.
Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF,
Krainer AR. 2010. Antisense correction of SMN2 splicing in
the CNS rescues necrosis in a type III SMA mouse model.
Genes Dev 24: 1634–1644.
Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, Krainer
AR. 2011. Peripheral SMN restoration is essential for long-
term rescue of a severe spinal muscular atrophy mouse
model. Nature 478: 123–126.
Jodelka FM, Ebert AD, Duelli DM, Hastings ML. 2010. A
feedback loop regulates splicing of the spinal muscular atro-
phy-modifying gene, SMN2. Hum Mol Genet 19: 4906–4917.
Kole R, Krainer AR, Altman S. 2012. RNA therapeutics: Beyond
RNA interference and antisense oligonucleotides. Nat Rev
Drug Discov 11: 125–140.
Kummer TT, Misgeld T, Lichtman JW, Sanes JR. 2004. Nerve-
independent formation of a topologically complex postsyn-
aptic apparatus. J Cell Biol 164: 1077–1087.
Le TT, McGovern VL, Alwine IE, Wang X, Massoni-Laporte A,
Rich MM, Burghes AH. 2011. Temporal requirement for high
SMN expression in SMA mice. Hum Mol Genet 20: 3578–
3591.
Ling KK, Gibbs RM, Feng Z, Ko CP. 2012. Severe neuromuscular
denervation of clinically relevant muscles in a mouse model
of spinal muscular atrophy. Hum Mol Genet 21: 185–195.
Lunn MR, Wang CH. 2008. Spinal muscular atrophy. Lancet
371: 2120–2133.
Lutz CM, Kariya S, Patruni S, Osborne MA, Liu D, Henderson
CE, Li DK, Pellizzoni L, Rojas J, Valenzuela DM, et al. 2011.
Postsymptomatic restoration of SMN rescues the disease
phenotype in a mouse model of severe spinal muscular
atrophy. J Clin Invest 121: 3029–3041.
Antisense modeling of disease
GENES & DEVELOPMENT 1883
 Cold Spring Harbor Laboratory Press on November 3, 2017 - Published by genesdev.cshlp.orgDownloaded from 
Muntoni F, Wood MJ. 2011. Targeting RNA to treat neuromus-
cular disease. Nat Rev Drug Discov 10: 621–637.
Nornes HO, Carry M. 1978. Neurogenesis in spinal cord of
mouse: An autoradiographic analysis. Brain Res 159: 1–6.
Park GH, Kariya S, Monani UR. 2010a. Spinal muscular atrophy:
New and emerging insights from model mice. Curr Neurol
Neurosci Rep 10: 108–117.
Park GH, Maeno-Hikichi Y, Awano T, Landmesser LT, Monani
UR. 2010b. Reduced survival of motor neuron (SMN) protein
in motor neuronal progenitors functions cell autonomously
to cause spinal muscular atrophy in model mice expressing
the human centromeric (SMN2) gene. J Neurosci 30: 12005–
12019.
Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek
LM, Hua Y, Rigo F, Matson J, Hung G, et al. 2011. Antisense
oligonucleotides delivered to the mouse CNS ameliorate
symptoms of severe spinal muscular atrophy. Sci Transl
Med 3: 72ra18. doi: 10.1126/scitranslmed.3001777.
Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J,
Garbes L, Fritzsche I, Mende Y, Blumcke I, Hahnen E, et al.
2010. SAHA ameliorates the SMA phenotype in two mouse
models for spinal muscular atrophy. Hum Mol Genet 19:
1492–1506.
Rudnik-Schoneborn S, Heller R, Berg C, Betzler C, Grimm T,
Eggermann T, Eggermann K, Wirth R, Wirth B, Zerres K.
2008. Congenital heart disease is a feature of severe infantile
spinal muscular atrophy. J Med Genet 45: 635–638.
Ruggiu M, McGovern VL, Lotti F, Saieva L, Li DK, Kariya S,
Monani UR, Burghes AH, Pellizzoni L. 2012. A role for SMN
exon 7 splicing in the selective vulnerability of motor
neurons in spinal muscular atrophy. Mol Cell Biol 32: 126–
138.
Sandy P, Ventura A, Jacks T. 2005. Mammalian RNAi: A
practical guide. Biotechniques 39: 215–224.
Steele AD, Jackson WS, King OD, Lindquist S. 2007. The power
of automated high-resolution behavior analysis revealed by
its application to mouse models of Huntington’s and prion
diseases. Proc Natl Acad Sci 104: 1983–1988.
Stewart PA, Hayakawa EM. 1987. Interendothelial junctional
changes underlie the developmental ‘tightening’ of the
blood–brain barrier. Brain Res 429: 271–281.
Wan L, Ottinger E, Cho S, Dreyfuss G. 2008. Inactivation of the
SMN complex by oxidative stress. Mol Cell 31: 244–254.
Zhang Z, Lotti F, Dittmar K, Younis I, Wan L, KasimM, Dreyfuss
G. 2008. SMN deficiency causes tissue-specific perturba-
tions in the repertoire of snRNAs and widespread defects in
splicing. Cell 133: 585–600.
Sahashi et al.
1884 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on November 3, 2017 - Published by genesdev.cshlp.orgDownloaded from 
 10.1101/gad.197418.112Access the most recent version at doi:
 26:2012, Genes Dev. 
  
Kentaro Sahashi, Yimin Hua, Karen K.Y. Ling, et al. 
  
diseases in animals
TSUNAMI: an antisense method to phenocopy splicing-associated
  
Material
Supplemental
  
 http://genesdev.cshlp.org/content/suppl/2012/08/13/26.16.1874.DC1
  
References
  
 http://genesdev.cshlp.org/content/26/16/1874.full.html#ref-list-1
This article cites 35 articles, 9 of which can be accessed free at:
  
License
Service
Email Alerting
  
 click here.right corner of the article or 
Receive free email alerts when new articles cite this article - sign up in the box at the top
Copyright © 2012 by Cold Spring Harbor Laboratory Press
 Cold Spring Harbor Laboratory Press on November 3, 2017 - Published by genesdev.cshlp.orgDownloaded from 
